ATX 101 - Aurobac Therapeutics
Alternative Names: ATX-101 - Aurobac TherapeuticsLatest Information Update: 08 Jul 2024
At a glance
- Originator Aurobac Therapeutics
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Sepsis